Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
Stocks · News reference
Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
Health Canada approval of new 0.05% cream formulation expands the ZORYVE portfolio to include a once-daily, steroid-free option for younger childrenThe 0.05% formulation was specifically selected for young children,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Arcutis Biotherapeutics shares are trading higher after Cantor Fitzgerald initiated its coverage on the stock with an Overweight rating and announced a price target of $48.
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy.